PARK Recombinant Proteins 

The PARK (Parkinson’s Disease) family of proteins includes key molecules such as PARK2 (parkin), PARK7 (DJ-1), and PINK1, which are involved in mitochondrial quality control, oxidative stress response, and protein degradation pathways. Dysregulation or mutations in these proteins are associated with familial and sporadic forms of Parkinson’s disease and other neurodegenerative disorders.

Content of PARK Recombinant Proteins

• Production:
  • Recombinant PARK proteins are expressed in E. coli, insect, or mammalian systems to ensure proper folding and activity.
  • Purification is achieved using affinity chromatography (e.g., His-tag or GST-tag purification).
• Variants:
  • Wild-type proteins for studying their physiological functions.
  • Mutant variants mimicking disease-related mutations (e.g., PARK2 R275W or PINK1 G309D) to model pathological conditions.
  • Domain-specific fragments for functional and interaction studies.
• Specifications:
  • Purity: Typically >95% confirmed by SDS-PAGE or HPLC.
  • Activity: Validated via enzymatic or binding assays (e.g., ubiquitination for PARK2, kinase assays for PINK1).
  • Storage: Formulated for stability at -80°C in buffers optimized for activity retention.

Applications of PARK Recombinant Proteins

• Neurodegenerative Disease Research:
  • Used to investigate molecular mechanisms of Parkinson’s disease, including protein aggregation, oxidative stress response, and mitochondrial dysfunction.
  • Enables studies on how PARK proteins mitigate cellular damage under stress conditions.
• Drug Discovery and Screening:
  • High-throughput screening for small molecules or peptides targeting PARK proteins for therapeutic development in Parkinson’s disease.
  • PARK2 ubiquitination activity and PINK1 kinase activity assays for evaluating potential drugs.
• Protein-Protein Interaction Studies:
  • PARK proteins are used to identify interaction partners involved in mitochondrial quality control, such as PINK1-parkin interactions in mitophagy.
  • Analysis of binding dynamics using surface plasmon resonance (SPR) or co-immunoprecipitation.

PARK recombinant proteins are essential tools for understanding the molecular mechanisms driving Parkinson’s disease and other neurodegenerative disorders. They support diverse applications in research, drug discovery, and diagnostic development, making them indispensable for advancing therapeutic strategies.